[Comparison of two multi-drug chemotherapy regimens based on mitoxantrone and epirubicin in 44 patients with non-Hodgkin's lymphoma].
From June 1987 to June 1989, a comparative study was carried out in 44 NON = Hodgkin's lymphoma patients to-evaluate the effect and side effects of two multi-drug chemotherapy regimens: Group A (cyclophosphamide, mitoxantrone, vincristine, prednisone) and Group B (cyclophosphamide, epirubicin, vincristine, prednisone). The response rate was 86% in Group A (22 patients) and was 82% in Group B (22 patients). By the end of August, 1989, 12 patients in Group A were still alive with a median survival of 16 (5-24) months while 18 patients in Group B were living with a median survival of 15 (4-24) months. The side effects were tolerable in both groups. From the authors' data, mitoxantrone is considered as effective as epirubicin for Non-Hodgkin's lymphoma.
Gao
H R
HR
Cancer Hospital, Shanghai Medical University.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage*; D014750:Vincristine / Q000008:administration & dosage
D015251:Epirubicin; D014750:Vincristine; D003520:Cyclophosphamide; D008942:Mitoxantrone